Small Molecules
9 September 2014
Serodus Announces Positive Phase IIa Clinical Study Results On SER100 In Patients with Systolic Hypertension9 September 2014
PTC Therapeutics Completes Enrollment of Landmark Trial in Duchenne Muscular Dystrophy9 September 2014
Galena Biopharma Doses First Patient in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial8 September 2014
TESARO Announces Submission of Rolapitant New Drug Application (NDA) to U.S. Food and Drug Administration8 September 2014
GenSpera Presents Mipsagargin (G-202) HCC Clinical Trial Update at 8th International Liver Cancer Association Conference8 September 2014
KemPharm, Inc. Advances KP201 Clinical Program with Initiation of Human Abuse Liability and Human Gastrointestinal Motility Trials8 September 2014
Novan’s Nitric Oxide Drug Candidate Inhibits Growth of Papillomavirus in Translational Animal Model8 September 2014
Novartis data at ERS 2014 show once-daily Ultibro® Breezhaler® is superior in reducing COPD flare ups compared to Seretide8 September 2014
Melinta Therapeutics Reports on PK Profile of a Single Oral Dose of Delafloxacin in Support of U.S. Phase 3 Gonorrhea Program8 September 2014
BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting8 September 2014
Safety and Sustained Benefits of Adempas® From Bayer Confirmed by Results of Long-Term Studies5 September 2014
Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN5 September 2014
Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia4 September 2014
Mallinckrodt Pharmaceutical’s MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination, Shows Efficacy in Phase 3 Acute Pain Trial4 September 2014
Mirati Therapeutics Initiates Phase 1 Study of MGCD516 for Non-Small Cell Lung Cancer and Other Advanced Solid Tumors4 September 2014
Novira Therapeutics Announces Successful Completion of Phase 1a Clinical Study of NVR-1221 and Commencement of Phase 1b Clinical Studies4 September 2014
Cleave Biosciences Initiates Phase 1 Clinical Trial of CB-5083 in Patients with Multiple MyelomaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports